-
ASCO GU 2021: Updated results of postoperative assisted chemotherapy Phase III POUT trial results for upper urinary tract tract skin cancer
Time of Update: 2021-02-24
Birtle summed up the latest analysis of phase III clinical trials in POUT and concluded that the benefits of complementary chemotherapy for disease-free and metastasis-free survival were maintained through additional follow-up.
-
The world's first oral PI3K/CK1 inhibitor once a day has been approved by the FDA for the treatment of lymphoma
Time of Update: 2021-02-24
MZL is generally considered a chronic incurable disease, with about 8,200 newly diagnosed patients in the United States each year.
FL is usually incurable because patients with this form of lymphoma can survive for many years and are therefore considered a chronic disease.
-
Eur Radiol: How to layer the risk of malignant breast non-lump lesions?
Time of Update: 2021-02-24
The newly developed classification system in this study, which combines the US and target characteristics of breast NMLs, can layer cancer risk according to BI-RADS categories, thus helping to clinically interpret and manage all NMLs detected on mammary US, providing technical support for further consensus.
-
Br J Cancer: Socio-demographic differences in tumor stages and their effects on the population when diagnosed in 10 solid tumor patients
Time of Update: 2021-02-24
by eliminating socio-demographic inequalities, the researchers eventually analyzed that 61 percent of patients with 10 solid tumors were diagnosed with phase I/II, narrowing the target gap to 14 percent.
-
JCO: Pegilo decakin and FOLFOX second-line therapy failed to improve the efficacy of giesythabin incurable metastatic pancreatic cancer
Time of Update: 2021-02-24
Pegilodecakin (PEG) combined calcium folate, fluorouracil and FOLFOX for second-line treatment of Gisitabin refractional pancreatic cancer (PDAC), failed to improve its OS, PFS or ORR, and no new safety signals were observed.
-
JCO: Chemotherapy combined with primary tumor removal does not improve the efficacy of patients with advanced colorectal cancer
Time of Update: 2021-02-24
The study looked at the advantages of PTR combined chemotherapy over chemotherapy alone in patients with asymptomatic CRC in stage IV that could not be removed and in patients with three or fewer non-removable metastatic diseases limited to liver, lung, and distant lymph node metastasis.
-
ASCO GU 2021: Nivolumab combined with Cabozantinib and Schoinidinib in late-stage renal cell carcinoma (CheckMate 9ER study)
Time of Update: 2021-02-24
the authors concluded that, in addition to previously provided data showing the advantages of progress-free and overall lifetime, patients treated with nivolumab and Cabozantinib had statistically significant HRQoL benefits compared to patients treated with schoinib.
-
ASCO GU 2021: What is the effectiveness of immunotherapy in the first line of metastatic renal cell carcinoma?
Time of Update: 2021-02-24
Gan provided the following concluding statement for the presentation: Although the immunotherapy/VEGF inhibitor combination has a longer duration of treatment and a higher objective response rate, there is no difference between the total survival rate and the next treatment time between the nivolumab plus ipilimumab combination and the immunotherapy/VEGF inhibitor combination in the IMDC moderate/low-risk population.
-
ASCO GU 2021: Immune joint targeting was successful in advanced kidney cancer, with the results of 2 years of treatment announced (KEYNOTE-426 study)
Time of Update: 2021-02-24
The KEYNOTE-426 study included 861 patients with advanced renal cell carcinoma who received first-line treatment, with Karnofsky Performance Score (KPS) ≥70% and Pembrolizumab (200 mg intravenous Q3W, up to 35 cycles) randomly assigned a 1:1 ratio The treatment of axitinib (5 mg oral BID) (n?432) or sunitinib treatment (50 mg oral QD, 4 weeks /2 weeks of suspension) (n=429) until the disease progresses, is not resistant to toxicity, the researcher and the patient decide to stop the drug, etc.
-
ASCO GU 2021: Results of late or metastatic urethroid skin cancer in the Adiliju monotherapy bureau (IMvigor 130 study)
Time of Update: 2021-02-24
same time, although the IMvigor130 study reached the end of the common primary study in PFS, the data were not stunning that the total lifetime of Atezolizumab single-drug therapy (Arm B) could not be formally evaluated, but good results were observed in IC2/3 patients.
-
ASCO GU 2021: ERLEADA in joint ZYTIGA treatment metastatic desopathic prostate cancer Phase III clinical
Time of Update: 2021-02-24
Johnson and Johnson Pharmaceuticals today published the results of a randomized, double-blind, placebo-controlled Phase III clinical (ACIS study) that reached the primary endpoint of radiological progression-free survival (rPFS), reducing the risk of death in patients with primary metastatic desopathic prostate cancer (mCRPC) by 31 percent.
-
ASCO GU 2021: IL-15R alphaFc super-excited agent N-803 studied in patients with NMIBC bladder cancer in place who responded to BCG (QUILT 3.032 trial)
Time of Update: 2021-02-24
in BCG non-reactive CIS patients (with or without Ta or T1 disease), all patients in the queue received in-bladder N-803 plus BCG, which met the standard induction/maintenance treatment options.
-
Nat Commun: CAR-T cells enhance the efficacy of immunotherapy by mediating the depletion of macrophages associated with immunosuppressive tumors
Time of Update: 2021-02-24
FR beta in TAMEs for ovarian cancer expresses that the current next-generation treatment strategies, including CAR-T (embedded antigen-subject T cells), can reprogram TME.
as an alternative to CAR-T therapy, which directly targets cancer cells, targeting TME non-tumor components has become an indirect treatment to limit tumor development.
-
Eur Radiol: A fast and accurate MRI program to diagnose colorectal cancer liver metastasis!
Time of Update: 2021-02-24
These tests were evaluated independently by two readers who were not aware of clinical data in two reading sessions: (1) the sequence obtained from all acquisitions (standard "long" scheme) and (2) only T2-weighted, dispersed weighted and liver and bile period images (simulated "short" scenarios).
-
European Radiology: About the malignantity of mumps lymphatic tissue-related lesions, let CT radiology tell you!
Time of Update: 2021-02-24
recently, a study published in the Journal of European Radiology developed and validated a preoperative radiological column map for preoperative identification of mumpsBLEL and MALToma, which combines CT radiological characteristics and clinical factors to provide clinical imaging for preoperative non-invasional assessment of mumps malignant lymphatic tissue lesions.
-
BMJ Open: Regular blood tests can be used for screening for advanced liver disease
Time of Update: 2021-02-24
In the study, researchers performed a Logistic regression analysis of blood data routinely collected by the University Hospital of Southampton (UHS) information system and based it on the AdvLD model, and then validated predictions of first severe liver events (SLE) in two queues of 394,253 (UHS: primary and secondary care) and 183,045 (CHIE: primary care care and health information).
-
Cell Death Differ: KDM4C promotes radiation resistance to lung cancer through an observational genetic modification
Time of Update: 2021-02-24
more importantly, knocking out USP9X disrupts the stability of KDM4C in lung cancer cells, thereby impairing the TGF-beta 2/Smad signal transducting path and the production of radiotherapy resistance.
in summary, the results show that USP9X-mediated KDM4C de-ubixination activates the TGF-beta 2/Smad signal transduct path and promotes radiotherapy resistance.
-
ASCO GU 2021: Lu-177 radiotherapy illuminates the path of radiation therapy for prostate cancer
Time of Update: 2021-02-24
As already mentioned, Dr. Sathekge stressed the importance of multidisciplinary participation in patient selection, including appropriate imaging findings, positive treatment for tumor progression, appropriate blood, kidney and liver function, and appropriate disease adaptation (mCRPC).
-
Br J Cancer: The medicinal level IgG weakens the anti-cancer activity of Osaliplat against colon cancer cells
Time of Update: 2021-02-24
medicinal level IgG reduced Osali platinum-induced cell death by evaluating the combination of medicinal levels IgG (such as PRIVIGEN®IgG and Tonglu®IgG) with chemotherapy, the researchers did not directly observe any significant effect of IgG on tumor cell viability.
-
ASCO GU 2021: Fixed dose of Durvalumab single drug for the treatment of urethra tumors has good safety (STRONG study)
Time of Update: 2021-02-24
Following advances in platinum chemotherapy (CT), durvalumab (anti-PD-L1) has been approved for the treatment of metastatic urethra skin cancer (mUC) (see: NEJM:avelumab for maintenance treatment after chemotherapy in patients with advanced urethra) (ASCO 2020 advanced urethrial skin cancer has made new progress, and Avel Aumab maintenance therapy combined with BSC can extend total survival by 7.1 months!
